https://mindmedicinelaw.com/briefing/israel-s-health-ministry-launches-national-psychedelic-ptsd-trial-20261025-53723The Psychedelic Journalen2026-10-25T15:05:13.883479+00:00Israel’s Health Ministry Launches National Psychedelic PTSD Trialisrael health ministry, psychedelic clinical trial, ptsd treatment, government policy, public health integration, clinical research, mdma, psilocybin, mental health innovationhttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-nears-potential-fda-approval-in-the-us-20261023-53220The Psychedelic Journalen2026-10-23T22:04:21.564040+00:00MDMA-Assisted Therapy Nears Potential FDA Approval in the USmdma-assisted therapy, fda approval, psychedelic regulation, clinical trials, dea rescheduling, ptsd treatment, risk mitigation, health policy, lykos therapeutics, psychedelic medicinehttps://mindmedicinelaw.com/briefing/mri-biomarkers-in-schizophrenia-and-trd-limited-clinical-utility-20261022-53664The Psychedelic Journalen2026-10-25T15:06:32.885155+00:00MRI Biomarkers in Schizophrenia and TRD: Limited Clinical Utilitymri biomarkers, schizophrenia, treatment-resistant depression, hippocampal alterations, prefrontal cortex, psychedelic trials, neuroimaging endpoints, biomarker validation, clinical translationhttps://mindmedicinelaw.com/briefing/novel-benzodiazepines-and-severe-outcomes-in-nsw-surveillance-study-findings-20261022-53297The Psychedelic Journalen2026-10-24T15:06:05.353845+00:00Novel Benzodiazepines and Severe Outcomes in NSW: Surveillance Study Findingsnovel benzodiazepines, bromazolam, public health surveillance, drug policy australia, clinical toxicology, harm reduction, polysubstance use, risk ratio methodology, nsw drug trendshttps://mindmedicinelaw.com/briefing/neural-complexity-metrics-implications-for-psychedelic-brain-research-20261022-53312The Psychedelic Journalen2026-10-24T15:05:53.580596+00:00Neural Complexity Metrics: Implications for Psychedelic Brain Researchneural complexity, brain network analysis, psychedelic research, observational metrics, perturbational metrics, clinical trial design, consciousness, small-world networks, mechanistic studieshttps://mindmedicinelaw.com/briefing/psychedelic-use-outside-clinics-epidemiology-and-policy-gaps-20261022-53278The Psychedelic Journalen2026-10-24T15:05:41.764161+00:00Psychedelic Use Outside Clinics: Epidemiology and Policy Gapspsychedelic epidemiology, non-clinical use, public health surveillance, harm reduction, policy gaps, community experiences, adverse effects, population-level data, psychedelic risks, drug policyhttps://mindmedicinelaw.com/briefing/genetic-biomarkers-and-antidepressant-response-implications-for-psychedelic-psyc-20261021-53669The Psychedelic Journalen2026-10-25T15:06:47.779350+00:00Genetic Biomarkers and Antidepressant Response: Implications for Psychedelic Psychiatrypolygenic scores, major depressive disorder, ssri response, genetic biomarkers, precision psychiatry, psychedelic research, gabaergic pathway, personalized medicine, pharmacogenomics, clinical trialshttps://mindmedicinelaw.com/briefing/dextromethorphan-bupropion-vs-esketamine-us-mdd-cost-outcomes-20261021-53670The Psychedelic Journalen2026-10-25T15:05:30.861894+00:00Dextromethorphan-Bupropion vs Esketamine: US MDD Cost Outcomesdextromethorphan-bupropion, auvelity, esketamine, major depressive disorder, healthcare costs, claims data, comparative effectiveness, payer policy, real-world evidence, psychedelic researchhttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-for-ptsd-us-evidence-review-2010-2025-20261021-53281The Psychedelic Journalen2026-10-24T15:05:02.988848+00:00MDMA-Assisted Therapy for PTSD: US Evidence Review 2010–2025mdma-assisted therapy, ptsd, integrative review, clinical trials, evidence certainty, grade system, research sponsorship, adverse events, cochrane review, regulatory policyhttps://mindmedicinelaw.com/briefing/media-vs-clinical-evidence-psilocybin-efficacy-and-risk-reporting-20261020-53648The Psychedelic Journalen2026-10-25T15:05:44.055975+00:00Media vs. Clinical Evidence: Psilocybin Efficacy and Risk Reportingpsilocybin clinical trials, media reporting, psychedelic therapy risks, evidence communication, public health policy, systematic review, mental health indications, safety reporting, research ethicshttps://mindmedicinelaw.com/briefing/ketset-trial-psychedelic-vs-biomedical-framing-of-ketamine-in-sweden-20261020-53315The Psychedelic Journalen2026-10-24T15:04:50.060365+00:00KetSet Trial: Psychedelic vs Biomedical Framing of Ketamine in Swedenketamine, treatment-resistant depression, psychedelic framing, biomedical framing, clinical trial, subjective experience, set and setting, health economics, Sweden, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-habenula-activity-implications-for-depression-policy-20261019-53684The Psychedelic Journalen2026-10-25T15:05:58.046163+00:00Ketamine’s Impact on Habenula Activity: Implications for Depression Policyketamine, habenula, depression, mechanism of action, psychiatric policy, clinical trials, FDA, biomarkers, neuroimaging, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/psychedelics-delay-neurovascular-coupling-implications-for-fmri-research-20261016-53291The Psychedelic Journalen2026-10-24T15:05:28.999613+00:00Psychedelics Delay Neurovascular Coupling: Implications for fMRI Researchpsychedelics, neurovascular coupling, fMRI, LSD, DMT, serotonin receptors, clinical trial design, regulatory science, hemodynamic delay, neuroimaging analysishttps://mindmedicinelaw.com/briefing/eeg-study-reveals-context-dependent-alpha-band-effects-of-psilocybin-20261016-53302The Psychedelic Journalen2026-10-24T15:05:15.499540+00:00EEG Study Reveals Context-Dependent Alpha-Band Effects of Psilocybinpsilocybin, eeg, alpha-band connectivity, context effects, clinical trial design, set and setting, neural mechanisms, sensory input, psychedelic neurosciencehttps://mindmedicinelaw.com/briefing/psilocybin-neuroplasticity-without-hallucinations-5-ht2a-layer-5-insights-20261015-53626The Psychedelic Journalen2026-10-25T15:06:17.127815+00:00Psilocybin: Neuroplasticity Without Hallucinations—5-HT2A Layer 5 Insightspsilocybin, 5-HT2A receptor, layer 5 pyramidal neurons, neuroplasticity, hallucinogenic effects, psychedelic drug development, clinical trial design, biomarkers, regulatory strategy